Xanthine oxidoreductase is an endogenous regulator of cyclooxygenase-2

Toshio Ohtsubo, Ilsa I. Rovira, Matthew F. Starost, Chengyu Liu, Toren Finkel

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Xanthine oxidoreductase (XOR) is the enzyme responsible for the final step in purine degradation resulting in the generation of uric acid. Here we have generated mice deficient in XOR. As expected, these animals lack tissue XOR activity and have low to undetectable serum levels of uric acid. Although normal at birth, XOR-/- mice fail to thrive after 10 to 14 days, and most die within the first month. The cause of death appears to be a form of severe renal dysplasia, a phenotype that closely resembles what has been observed previously in cyclooxygenase-2 (COX-2)-deficient mice. We further demonstrate that in the first month of life, a period in which the mouse kidney is undergoing rapid maturation and remodeling, wild-type mice exhibit an ≈30-fold increase in renal XOR activity, with a corresponding induction of COX-2 expression. In contrast, during this same period, XOR-/- animals fail to augment renal COX-2 expression. Finally, we show that in vitro and in vivo, uric acid can stimulate basal COX-2 expression. These results demonstrate that XOR activity is an endogenous physiological regulator of COX-2 expression and thereby provide insight into previous epidemiological evidence linking elevated serum uric levels with systemic hypertension and increased mortality from cardiovascular diseases. In addition, these results suggest a novel molecular link between cellular injury and the inflammatory response.

Original languageEnglish
Pages (from-to)1118-1124
Number of pages7
JournalCirculation research
Volume95
Issue number11
DOIs
Publication statusPublished - Nov 26 2004

Fingerprint

Xanthine Dehydrogenase
Cyclooxygenase 2
Uric Acid
Kidney
Serum
Cause of Death
Cardiovascular Diseases
Parturition
Hypertension
Phenotype
Mortality
Wounds and Injuries
Enzymes

All Science Journal Classification (ASJC) codes

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Ohtsubo, T., Rovira, I. I., Starost, M. F., Liu, C., & Finkel, T. (2004). Xanthine oxidoreductase is an endogenous regulator of cyclooxygenase-2. Circulation research, 95(11), 1118-1124. https://doi.org/10.1161/01.RES.0000149571.96304.36

Xanthine oxidoreductase is an endogenous regulator of cyclooxygenase-2. / Ohtsubo, Toshio; Rovira, Ilsa I.; Starost, Matthew F.; Liu, Chengyu; Finkel, Toren.

In: Circulation research, Vol. 95, No. 11, 26.11.2004, p. 1118-1124.

Research output: Contribution to journalArticle

Ohtsubo, T, Rovira, II, Starost, MF, Liu, C & Finkel, T 2004, 'Xanthine oxidoreductase is an endogenous regulator of cyclooxygenase-2', Circulation research, vol. 95, no. 11, pp. 1118-1124. https://doi.org/10.1161/01.RES.0000149571.96304.36
Ohtsubo, Toshio ; Rovira, Ilsa I. ; Starost, Matthew F. ; Liu, Chengyu ; Finkel, Toren. / Xanthine oxidoreductase is an endogenous regulator of cyclooxygenase-2. In: Circulation research. 2004 ; Vol. 95, No. 11. pp. 1118-1124.
@article{212946908cdc4a56b7fffe4d60c29530,
title = "Xanthine oxidoreductase is an endogenous regulator of cyclooxygenase-2",
abstract = "Xanthine oxidoreductase (XOR) is the enzyme responsible for the final step in purine degradation resulting in the generation of uric acid. Here we have generated mice deficient in XOR. As expected, these animals lack tissue XOR activity and have low to undetectable serum levels of uric acid. Although normal at birth, XOR-/- mice fail to thrive after 10 to 14 days, and most die within the first month. The cause of death appears to be a form of severe renal dysplasia, a phenotype that closely resembles what has been observed previously in cyclooxygenase-2 (COX-2)-deficient mice. We further demonstrate that in the first month of life, a period in which the mouse kidney is undergoing rapid maturation and remodeling, wild-type mice exhibit an ≈30-fold increase in renal XOR activity, with a corresponding induction of COX-2 expression. In contrast, during this same period, XOR-/- animals fail to augment renal COX-2 expression. Finally, we show that in vitro and in vivo, uric acid can stimulate basal COX-2 expression. These results demonstrate that XOR activity is an endogenous physiological regulator of COX-2 expression and thereby provide insight into previous epidemiological evidence linking elevated serum uric levels with systemic hypertension and increased mortality from cardiovascular diseases. In addition, these results suggest a novel molecular link between cellular injury and the inflammatory response.",
author = "Toshio Ohtsubo and Rovira, {Ilsa I.} and Starost, {Matthew F.} and Chengyu Liu and Toren Finkel",
year = "2004",
month = "11",
day = "26",
doi = "10.1161/01.RES.0000149571.96304.36",
language = "English",
volume = "95",
pages = "1118--1124",
journal = "Circulation Research",
issn = "0009-7330",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Xanthine oxidoreductase is an endogenous regulator of cyclooxygenase-2

AU - Ohtsubo, Toshio

AU - Rovira, Ilsa I.

AU - Starost, Matthew F.

AU - Liu, Chengyu

AU - Finkel, Toren

PY - 2004/11/26

Y1 - 2004/11/26

N2 - Xanthine oxidoreductase (XOR) is the enzyme responsible for the final step in purine degradation resulting in the generation of uric acid. Here we have generated mice deficient in XOR. As expected, these animals lack tissue XOR activity and have low to undetectable serum levels of uric acid. Although normal at birth, XOR-/- mice fail to thrive after 10 to 14 days, and most die within the first month. The cause of death appears to be a form of severe renal dysplasia, a phenotype that closely resembles what has been observed previously in cyclooxygenase-2 (COX-2)-deficient mice. We further demonstrate that in the first month of life, a period in which the mouse kidney is undergoing rapid maturation and remodeling, wild-type mice exhibit an ≈30-fold increase in renal XOR activity, with a corresponding induction of COX-2 expression. In contrast, during this same period, XOR-/- animals fail to augment renal COX-2 expression. Finally, we show that in vitro and in vivo, uric acid can stimulate basal COX-2 expression. These results demonstrate that XOR activity is an endogenous physiological regulator of COX-2 expression and thereby provide insight into previous epidemiological evidence linking elevated serum uric levels with systemic hypertension and increased mortality from cardiovascular diseases. In addition, these results suggest a novel molecular link between cellular injury and the inflammatory response.

AB - Xanthine oxidoreductase (XOR) is the enzyme responsible for the final step in purine degradation resulting in the generation of uric acid. Here we have generated mice deficient in XOR. As expected, these animals lack tissue XOR activity and have low to undetectable serum levels of uric acid. Although normal at birth, XOR-/- mice fail to thrive after 10 to 14 days, and most die within the first month. The cause of death appears to be a form of severe renal dysplasia, a phenotype that closely resembles what has been observed previously in cyclooxygenase-2 (COX-2)-deficient mice. We further demonstrate that in the first month of life, a period in which the mouse kidney is undergoing rapid maturation and remodeling, wild-type mice exhibit an ≈30-fold increase in renal XOR activity, with a corresponding induction of COX-2 expression. In contrast, during this same period, XOR-/- animals fail to augment renal COX-2 expression. Finally, we show that in vitro and in vivo, uric acid can stimulate basal COX-2 expression. These results demonstrate that XOR activity is an endogenous physiological regulator of COX-2 expression and thereby provide insight into previous epidemiological evidence linking elevated serum uric levels with systemic hypertension and increased mortality from cardiovascular diseases. In addition, these results suggest a novel molecular link between cellular injury and the inflammatory response.

UR - http://www.scopus.com/inward/record.url?scp=9344250533&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9344250533&partnerID=8YFLogxK

U2 - 10.1161/01.RES.0000149571.96304.36

DO - 10.1161/01.RES.0000149571.96304.36

M3 - Article

VL - 95

SP - 1118

EP - 1124

JO - Circulation Research

JF - Circulation Research

SN - 0009-7330

IS - 11

ER -